Literature DB >> 18845557

Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.

Urs Meyer1, Erica Spoerri, Benjamin K Yee, Markus J Schwarz, Joram Feldon.   

Abstract

Current pharmacotherapy of schizophrenia remains unsatisfactory with little hope for complete functional restoration in patients once the disease has developed. A preventive approach based on intervention in the prodromal stage of the disease aiming to preserve functional integrity by halting the progress of the disease is therefore extremely attractive. Here, we investigated the effects of preventive antipsychotic or antidepressant drug treatment in a well-established neurodevelopmental mouse model of multiple schizophrenia-related abnormalities. Pregnant mice on gestation day 9 were exposed to the viral mimic polyriboinosinic-polyribocytidylic acid (2 mg/kg, intravenously) or corresponding vehicle treatment, and the resulting offspring from both prenatal treatment conditions were subjected to chronic antipsychotic (haloperidol or clozapine), antidepressant (fluoxetine), or placebo treatment during the periadolescent stage of development. The effects of the preventive pharmacotherapy on behavioral and pharmacological functions were then investigated in adulthood using paradigms relevant to schizophrenia, namely prepulse inhibition, latent inhibition, and sensitivity to psychostimulant drugs. We show that periadolescent treatment with the reference antipsychotic and antidepressant drugs can successfully block the emergence of multiple psychosis-related behavioral and pharmacological abnormalities in subjects predisposed to adult brain pathology by exposure to prenatal immune challenge. At the same time, however, our study reveals numerous negative influences of the early pharmacological intervention on normal behavioral development in control subjects. Hence, even though preventive pharmacotherapy may be beneficial in individuals with predisposition to psychosis-related brain dysfunctions, chronic antipsychotic or antidepressant drug treatment in false-positive subjects is associated with substantial risk for long-term behavioral disturbances in adulthood.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845557      PMCID: PMC2879685          DOI: 10.1093/schbul/sbn131

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  49 in total

1.  Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.

Authors:  E Spina; A Avenoso; G Facciolà; M G Scordo; M Ancione; A G Madia; A Ventimiglia; E Perucca
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

Review 2.  Treatment of the schizophrenia prodrome: is it presently ethical?

Authors:  B A Cornblatt; T Lencz; J M Kane
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

3.  The schizophrenia prodrome: treatment and high-risk perspectives.

Authors:  Barbara Cornblatt; Todd Lencz; Michael Obuchowski
Journal:  Schizophr Res       Date:  2002-03-01       Impact factor: 4.939

Review 4.  Psychosis treatment prior to psychosis onset: ethical issues.

Authors:  T H McGlashan
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

Review 5.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

Review 6.  In utero infection and adult schizophrenia.

Authors:  Alan S Brown; Ezra S Susser
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2002

7.  Diagnosing schizophrenia in the initial prodromal phase.

Authors:  J Klosterkötter; M Hellmich; E M Steinmeyer; F Schultze-Lutter
Journal:  Arch Gen Psychiatry       Date:  2001-02

8.  Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring.

Authors:  Limin Shi; S Hossein Fatemi; Robert W Sidwell; Paul H Patterson
Journal:  J Neurosci       Date:  2003-01-01       Impact factor: 6.167

9.  Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients.

Authors:  Philipp A Csomor; Benjamin K Yee; Joram Feldon; Anastasia Theodoridou; Erich Studerus; Franz X Vollenweider
Journal:  Schizophr Bull       Date:  2008-01-31       Impact factor: 9.306

10.  Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group.

Authors:  Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Colleen A McFarlane; Mats Hallgren; Patrick D McGorry
Journal:  Schizophr Res       Date:  2003-03-01       Impact factor: 4.939

View more
  54 in total

Review 1.  The environment and susceptibility to schizophrenia.

Authors:  Alan S Brown
Journal:  Prog Neurobiol       Date:  2010-10-16       Impact factor: 11.685

2.  The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.

Authors:  Zeljka Korade; Hye-Young H Kim; Keri A Tallman; Wei Liu; Katalin Koczok; Istvan Balogh; Libin Xu; Karoly Mirnics; Ned A Porter
Journal:  J Med Chem       Date:  2016-01-29       Impact factor: 7.446

3.  Positive modulation of α5 GABAA receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide.

Authors:  Bojan Batinić; Anja Santrač; Ivan Jančić; Guanguan Li; Aleksandra Vidojević; Bojan Marković; James M Cook; Miroslav M Savić
Journal:  Int J Dev Neurosci       Date:  2017-06-10       Impact factor: 2.457

4.  A classification of sociomedical health indicators: perspectives for health administrators and health planners.

Authors:  A E Siegmann
Journal:  Int J Health Serv       Date:  1976       Impact factor: 1.663

5.  Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.

Authors:  Shinnyi Chou; Sean Jones; Ming Li
Journal:  Brain Res       Date:  2015-06-03       Impact factor: 3.252

6.  Prenatal immune challenge in rats: altered responses to dopaminergic and glutamatergic agents, prepulse inhibition of acoustic startle, and reduced route-based learning as a function of maternal body weight gain after prenatal exposure to poly IC.

Authors:  Charles V Vorhees; Devon L Graham; Amanda A Braun; Tori L Schaefer; Matthew R Skelton; Neil M Richtand; Michael T Williams
Journal:  Synapse       Date:  2012-05-15       Impact factor: 2.562

7.  Asenapine sensitization from adolescence to adulthood and its potential molecular basis.

Authors:  Qing Shu; Rongyin Qin; Yingzhu Chen; Gang Hu; Ming Li
Journal:  Behav Brain Res       Date:  2014-08-02       Impact factor: 3.332

8.  Induction of Toll-like receptor 3-mediated immunity during gestation inhibits cortical neurogenesis and causes behavioral disturbances.

Authors:  Joari De Miranda; Kavitha Yaddanapudi; Mady Hornig; Gabriel Villar; Robert Serge; W Ian Lipkin
Journal:  MBio       Date:  2010-10-05       Impact factor: 7.867

Review 9.  Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia.

Authors:  Urs Meyer; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2009-03-11       Impact factor: 4.530

10.  Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: evidence from MRI in a mouse model.

Authors:  Qi Li; Charlton Cheung; Ran Wei; Edward S Hui; Joram Feldon; Urs Meyer; Sookja Chung; Siew E Chua; Pak C Sham; Ed X Wu; Grainne M McAlonan
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.